A clinical study found that patients with advanced liver cancer benefited from ICT therapy (Qin et al., 2020), which promoted apoptosis in HCC by inhibiting alpha-fetoprotein (AFP) expression (Li et al., 2021b). This evidence concerns the gene AFP and hepatocellular carcinoma.